The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -11,131,448 |
| Loss on impairment of inventory included in cost of goods sold | 1,984,359 |
| Shares to be issued for services included in general and administrative | 142,800 |
| Change in the fair value of derivative conversion feature | -850,152 |
| Change in the fair value of obligation to issue shares | -1,487,328 |
| Foreign exchange gain | 66,252 |
| Interest expense | 1,958,785 |
| Imputed interest expense | 490,630 |
| Loss on the extinguishment of debt | 0 |
| Loss on impairment of investment | 4,518,127 |
| Gain on write-off of accounts payable and accrued liabilities | 410,430 |
| Other expense | 1,930,000 |
| Goods and services tax receivable | 11,125 |
| Accounts receivable | 1,011,297 |
| Inventory | 1,988,051 |
| Royalty payable | 303,525 |
| Accounts payable and accrued liabilities | 2,877,890 |
| Deferred revenue | 260,561 |
| Accrued interest | 0 |
| Cash used in operating activities | -789,102 |
| Purchase of equipment | 5,519 |
| Cash used in investing activities | -5,519 |
| Proceeds from notes payable | 0 |
| Proceeds from loans payable to related parties | 794,269 |
| Proceeds from convertible notes | 0 |
| Cash provided by financing activities | 794,269 |
| Net change in cash | -352 |
| Cash, beginning of year | 2,156 |
| Cash, end of year | 1,804 |
CANNAPHARMARX, INC. (CPMD)
CANNAPHARMARX, INC. (CPMD)